Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
J Gastroenterol Hepatol. 2010 Sep;25(9):1537-42. doi: 10.1111/j.1440-1746.2010.06289.x.
Few systematic studies have been published on prognosis and clinical outcome of gastric cancer patients with disseminated intravascular coagulation (DIC) as the first presentation of malignancy. We evaluated the clinicopathologic features and clinical outcomes of this population.
We reviewed the medical records of patients with metastatic or recurred gastric cancer that initially presented with DIC.
Twenty-one patients were included. Median age was 47 years (range, 24-72 years). Eighteen patients (85.7%) had bone metastasis, and nine patients (42.9%) had hemorrhagic complication of DIC. Fourteen patients received palliative chemotherapy, and seven patients received best supportive care (BSC). The most common factor influencing the decision to abandon the palliative chemotherapy was uncontrolled bleeding (57.1%). The median overall survival (OS) of all patients was 58 days (range, 2-342 days). The OS was significantly shorter in BSC than in the chemotherapy group (median, 16 vs 99 days, P < 0.001). In multivariate analysis, chemotherapy was independently associated with longer OS. In the chemotherapy group, the response to treatment was evaluable in 11 patients: two (18.2%) had a partial response, five (45.5%) had stable disease and four (36.4%) had progressive disease. The OS of patients with progressive disease was significantly longer in the chemotherapy group than in the BSC group (median, 92 vs 16 days, P = 0.009).
The prognosis is poor with gastric cancer that initially presents with DIC but palliative chemotherapy, compared with BSC, prolongs OS. Therefore, early and intensive management for correctable DIC followed by chemotherapy should be considered in this population.
鲜有系统研究报道过以弥散性血管内凝血(DIC)为首发恶性肿瘤表现的胃癌患者的预后和临床结局。我们评估了这部分患者的临床病理特征和临床结局。
我们回顾性分析了以 DIC 为首发表现的转移性或复发性胃癌患者的病历。
共纳入 21 例患者。中位年龄为 47 岁(范围,24-72 岁)。18 例(85.7%)患者有骨转移,9 例(42.9%)患者有 DIC 的出血并发症。14 例患者接受姑息化疗,7 例患者接受最佳支持治疗(BSC)。影响放弃姑息化疗决策的最常见因素是无法控制的出血(57.1%)。所有患者的中位总生存期(OS)为 58 天(范围,2-342 天)。BSC 组的 OS 明显短于化疗组(中位,16 与 99 天,P < 0.001)。多变量分析显示,化疗与 OS 延长独立相关。在化疗组中,11 例患者可评估治疗反应:2 例(18.2%)有部分缓解,5 例(45.5%)疾病稳定,4 例(36.4%)疾病进展。化疗组疾病进展患者的 OS 明显长于 BSC 组(中位,92 与 16 天,P = 0.009)。
以 DIC 为首发表现的胃癌患者预后较差,但与 BSC 相比,姑息化疗可延长 OS。因此,对于这部分患者,应考虑早期积极治疗可纠正的 DIC,随后进行化疗。